Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Obstetrics and Gynecology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Is menstruation obsolete?.Oxford University Press, New York1999
- Prevalence of childhood and adult obesity in the United States, 2011-2012.JAMA. 2014; 311: 806-814
- Committee opinion no. 549: obesity in pregnancy.Obstet Gynecol. 2013; 121: 213-217
- Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee.World Health Organ Tech Rep Ser. 1995; 854: 1-452
- Shifts in intended and unintended pregnancies in the United States, 2001-2008.Am J Public Health. 2014; 104: S43-S48
- Psychosocial and physical activity changes after gastric restrictive procedures for morbid obesity.Aust N Z J Surg. 1990; 60: 755-758
- Perceived changes in sexual functioning and body image following weight loss in an obese female population: a pilot study.J Sex Marital Ther. 1997; 23: 74-78
- Body mass index and sexual behavior.Obstet Gynecol. 2008; 112: 586-592
- Risky sexual behavior: a race-specific social consequence of obesity.J Youth Adolesc. 2012; 41: 41-52
- Family-planning practices among women with diabetes and overweight and obese women in the 2002 National Survey For Family Growth.Diabetes Care. 2009; 32: 1026-1031
- Contraceptive use and contraception type in women by body mass index category.Womens Health Issues. 2009; 19: 381-389
- The relationship between body mass index and unintended pregnancy: results from the 2002 National Survey of Family Growth.Contraception. 2008; 77: 234-238
- Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women.Obstet Gynecol. 2012; 120: 21-26
- Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.Contraception. 2015; 91: 274-279
- Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.Contraception. 2015; 91: 280-283
- Pharmacokinetics of the etonogestrel contraceptive implant in obese women.Am J Obstet Gynecol. 2012; 207: 110.e1-110.e6
- Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval.Contraception. 2004; 69: 3-7
- Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously.Contraception. 2010; 81: 487-495
- Contraceptive efficacy and safety of DMPA-SC.Contraception. 2004; 70: 269-275
- Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic–pituitary–ovarian activity.Contraception. 2009; 80: 119-127
- Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women.Contraception. 2010; 81: 474-480
- Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial.Obstet Gynecol. 2010; 116: 275-283
- Oral contraceptive effectiveness according to body mass index, weight, age, and other factors.Am J Obstet Gynecol. 2009; 201: 263.e1-263.e9
- Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen.Obstet Gynecol. 2011; 117: 33-40
- Association between efficacy and body weight or body mass index for two low-dose oral contraceptives.Contraception. 2009; 79: 424-427
- Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive.Contraception. 2012; 85: 235-239
- Contraceptive failures in overweight and obese combined hormonal contraceptive users.Obstet Gynecol. 2013; 121: 585-592
- Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women.Am J Obstet Gynecol. 2012; 207: 39.e1-39.e6
- Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women.Contraception. 2013; 87: 432-436
- Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles.Contraception. 2014; 90: 272-279
- Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data.Fertil Steril. 2002; 77: S13-S18
US Medical Eligibility Criteria 2010, adapted from World Health Organization Medical Eligibility Criteria. 4th edition. 2010. Available at: http://www.cdc.gov/reproductivehealth/UnintendedPregnancy/USMEC.htm. Accessed May 5, 2015.
World Health Organization. Medical eligibility criteria for contraceptive use: fourth edition. 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf. Accessed May 5, 2015.
UK Medical eligibility criteria for contraceptive use. 2009. Available at: http://www.fsrh.org/pdfs/UKMEC2009.pdf. Accessed May 5, 2015.
- Progestin-only contraception and venous thromboembolism.Thromb Res. 2012; 129: e257-e262
- Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use.Thromb Haemost. 2003; 89: 493-498
- Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations.Br J Haematol. 2007; 139: 289-296
- Oral contraceptives and venous thromboembolism: a five-year national case-control study.Contraception. 2002; 65: 187-196
- Venous thromboembolic disease in users of low-estrogen combined estrogen–progestin oral contraceptives.Contraception. 2004; 70: 3-10
- Much ado about little: obesity, combined hormonal contraceptive use and venous thrombosis.Contraception. 2008; 77: 143-146
- The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives.Eur J Contracept Reprod Health Care. 2000; 5: 265-274
- The incidence of first venous thromboembolism in and around pregnancy using linked primary and secondary care data: a population based cohort study from England and comparative meta-analysis.PLoS One. 2013; 8: e70310
- Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based nested case–control study.Thromb Res. 2007; 120: 505-509
- Combination contraceptives: effects on weight.Cochrane Database Syst Rev. 2014; (CD003987)
- Weight change at 12 months in users of three progestin-only contraceptive methods.Contraception. 2013; 88: 503-508
- Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation.Contraception. 1995; 51: 283-288
- Safety and efficacy of Implanon™, a single-rod implantable contraceptive containing etonogestrel.Contraception. 2005; 71: 319-326
- Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women.Am J Clin Nutr. 2001; 73: 19-26
- Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate.Obstet Gynecol. 2011; 117: 793-797
- Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive.Contraception. 2010; 81: 107-111
- Weight variation in a cohort of women using copper IUD for contraception.Contraception. 2003; 68: 27-30
- Postpartum weight retention risk factors and relationship to obesity at 1 year.Obstet Gynecol. 2015; 125: 144-152
Article info
Publication history
Published online: September 15, 2015
Footnotes
Disclosures: Dr P.S. Lotke serves on an international advisory board for Bayer Healthcare and as a clinical trainer for Nexplanon (Merck).
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
